A5043454259- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Research and Treatments
- Immune cells in cancer
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Ubiquitin and proteasome pathways
- Medical Imaging Techniques and Applications
- Cancer-related molecular mechanisms research
- Monoclonal and Polyclonal Antibodies Research
Clinica Universidad de Navarra
2021-2024
Universidad de Navarra
2020-2023
Mount Sinai Health System
2023
Navarre Institute of Health Research
2023
Center for Orthopaedics
2021
Abstract Background The identification of novel therapeutic strategies to overcome resistance the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes effects on Id1 protein, key factor involved oncogenic pathway, and investigates role acquired as well synergistic anticancer effect combined with immunotherapy -mutant LUAD. Methods We evaluated LUAD by Western blot, RNA-seq different syngeneic mouse models. Genetic modulation expression was...
The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from blockade, largely because immunosuppression. New immunotherapy-based combinations are under investigation an attempt to improve outcomes. Id1 (inhibitor differentiation 1) involved In this study, we explored the potential synergistic effect combination inhibition and pharmacological PD-L1 blockade three different syngeneic murine KRAS-mutant lung...
Harnessing the anti-tumor immune system response by targeting program cell death protein (PD-1) and ligand (PD-L1) axis has been a major breakthrough in non-small lung cancer (NSCLC) therapy. Nonetheless, conventional imaging tools cannot accurately assess immunotherapy-treated patients. Using syngeneic mouse model responder to immunotherapy, we aimed demonstrate that [89Zr]-anti-PD-1 immuno-PET is safe feasible modality PD-1/PD-L1 blockade NSCLC.A anti-PD-1 therapy was used. Tumor growth...
<title>Abstract</title> <bold>Background</bold> The identification of novel therapeutic strategies to overcome the intrinsic or acquired resistance trametinib in mutant <italic>KRAS</italic> lung adenocarcinoma (LUAD) is a major challenge. This study analyzes effects <italic>Id1</italic>, key factor involved oncogenic pathway, and investigates <italic>Id1</italic> role acquire synergy with immunotherapy <italic>KRAS</italic>-driven LUAD.<bold>Methods</bold> We evaluated...